-
Option Strategies to Consider When Implied Volatility Relatively Low 02-28-2011
Monday, February 28, 2011 - 7:57pm | 852Cusick's Corner The grind continues. If you are bullish and either raised cash from taking profits or just have some capital on the sidelines, what strategies could you consider? First take a look at implied volatility by going to the oX Volatility View and Chains. Overall market volatility is...
-
Salix Pharmaceuticals Reports Q4 EPS of $0.40 vs. $0.49
Monday, February 28, 2011 - 5:20pm | 30Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the fourth quarter ended December 31, 2010. Net product revenues $118,498,000 EPS of $0.40
-
Vivus Reports EPS of $(0.19) vs. $(0.22)
Monday, February 28, 2011 - 5:01pm | 87VIVUS, Inc. (Nasdaq: VVUS) today reported its highlights and financial results for the fourth quarter and year ended December 31, 2010. In the fourth quarter of 2009, net loss from continuing operations was of $15.5 million, or $0.19 per share, net income from discontinued operations of $2.3...
-
Stock on The Move: (CBRX) Breaking out New High Flag Formation
Monday, February 28, 2011 - 4:12pm | 18Stock on The Move: (CBRX) Breaking out New High Flag Formation...
-
XIAPEX Authorized in the European Union For Dupuytren's Contracture; Pfizer, Auxilium Have Marketing Rights
Monday, February 28, 2011 - 2:39pm | 104XIAPEX, a new non-surgical treatment option for Dupuytren's contracture in adult patients with a palpable cord, has been granted marketing authorization by the European Commission and is expected to be available for use in some European markets later this year.1 Collagenase clostridium...
-
Options Brief: Elan Corporation (ELN)
Monday, February 28, 2011 - 11:36am | 74Shares of Elan Corporation (NYSE: ELN) are higher on the session by 1.25%, trading at $6.46. Overall put volume is now running at 3.89x the daily average, with 2% of all puts traded being purchases on the offer. 1,225 contracts have traded on the session so far. Elan Corporation, plc is a...
-
Options Brief: Medicis Pharmaceutical (MRX)
Monday, February 28, 2011 - 11:26am | 91Shares of Medicis Pharmaceutical (NYSE: MRX) are higher on the session by 25.45%, trading at $32.39. Overall call volume is now running at 14.85x the daily average, with 44% of all calls traded being purchases on the offer. 7,512 contracts have traded on the session so far. Medicis Pharmaceutical...
-
Morning Market Movers (MRX, GLBS, NHP, PACR)
Monday, February 28, 2011 - 11:06am | 116Medicis Pharmaceutical Corp (NYSE: MRX) jumped 21.88%to $31.47 at 10:00 am. MRX reported a 22.4% surge in its 2010 revenue. Globus Maritime Limited (NASDAQ: GLBS) shares advanced 13.22% to $8.99. GLBS declared a Q4 cash dividend of $0.16 per share. Nationwide Health Properties Inc (NYSE: NHP)...
-
Shire Announce FDA Approval for INTUNIV Extended-Release Tablets
Monday, February 28, 2011 - 10:02am | 83Shire plc (NASDAQ: SHPGY) today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV Extended-Release Tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to 17...
-
Piper Jaffray Upgrades Medicis Pharmaceutical To Overweight; Raises PT To $38
Monday, February 28, 2011 - 9:54am | 176Piper Jaffray is upgrading Medicis (NYSE: MRX) to Overweight from Neutral and raising the PT to $38. With Friday's settlement with Teva on the Solodyn generic litigation, with Teva not launching its generics on the 65 and 115 mg doses until February 2018 and on the 55, 80 and 105 mg doses until...
-
UPDATE: Deutsche Bank Raises PT on Medicis Pharmaceutical to $36 (MRX)
Monday, February 28, 2011 - 9:22am | 123Deutsche Bank is out with its report today on Medicis Pharmaceutical (NYSE: MRX), raising its price target from $35 to $36. In a note to clients, Deutsche Bank writes, "We are updating our model based on trends for currently marketed products and the discontinuation of LipoSonix and Plexion. We are...
-
Piper Jaffray Upgrades Medicis Pharmaceuticals To Overweight, PT To $38
Monday, February 28, 2011 - 8:44am | 28Piper Jaffray has upgraded Medicis Pharmaceutical (NYSE: MRX) from Neutral to Overweight and has raised the price target from $30 to $38.
-
Endo Pharma Reports Upbeat Q4 Results
Monday, February 28, 2011 - 8:43am | 56Endo Pharma (NASDAQ: ENDP) reports its Q4 adjusted EPS at $1.06, beating the consensus of $0.96. ENDP reports its Q4 revenue at $511 million, versus the consensus of $482.76 million. ENDP shares gained 1.95% to $35.00 in pre-market trading. Read more from Benzinga's Company news.
-
Endo Pharmaceuticals Sees 2011 EPS of $4.20 and $4.30
Monday, February 28, 2011 - 8:43am | 40Endo (NASDAQ: ENDP) now estimates 2011 revenues to be between $2.35 billion and $2.45 billion, reported (GAAP) diluted earnings per share to be between $2.43 and $2.53 and adjusted diluted earnings per share to be between $4.20 and $4.30.
-
Endo Pharmaceuticals Reports Q4 EPS of $1.06 vs. $0.96
Monday, February 28, 2011 - 8:41am | 107Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the fourth quarter 2010. Total revenues during the fourth quarter of 2010 increased 31 percent to $511 million, compared with $391 million in the same quarter of 2009. Net income for the three months ended December 31, 2010...